Advertisement

Topics

NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla

07:39 EDT 19 Jun 2017 | SCRIP

After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA NICE will now decide...

      

Related Stories

 

Original Article: NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla

NEXT ARTICLE

More From BioPortfolio on "NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...